Xenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings Results

Xenon Pharmaceuticals (NASDAQ:XENE) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, hitting the consensus estimate of ($1.17), Zacks reports. During the same quarter in the prior year, the company earned ($0.83) earnings per share.

Here are the key takeaways from Xenon Pharmaceuticals’ conference call:

• Xenon’s Phase III X-TOLE2 for azetukalner (AZK) exceeded expectations with strong efficacy and tolerability, and the company plans an NDA submission in Q3 2026 with an anticipated U.S. launch in late 2027/early 2028 (standard FDA review + DEA scheduling).
• Long-term open-label data are compelling — ≥48-month patients showed a 91% median reduction in monthly focal seizures and ~40% were seizure-free for ≥12 months, supporting AZK’s potential differentiation and durable benefit.
• Xenon is expanding AZK’s opportunity beyond focal epilepsy — EXACT (primary generalized tonic‑clonic seizures) is enrolling and three Phase III depression studies (X‑NOVA 2 readout expected H1 2027) could materially broaden the addressable market if successful.
• Early-stage pain programs XEN1701 (NaV1.7) and XEN1120 (KV7) are completing first‑in‑human studies this year with plans to advance to Phase II acute pain POC trials, but these are early-stage and carry typical development risk.
• Financially strong after a $747.5M offering, Xenon ended Q1 with about $1.3 billion in cash and equivalents, which management says funds operations into 2029 and supports launch and pipeline advancement.

Xenon Pharmaceuticals Stock Performance

XENE stock traded down $2.59 during mid-day trading on Thursday, reaching $56.00. 576,359 shares of the stock traded hands, compared to its average volume of 917,107. Xenon Pharmaceuticals has a one year low of $28.19 and a one year high of $63.95. The stock has a market capitalization of $5.41 billion, a PE ratio of -12.84 and a beta of 0.65. The business has a 50-day moving average price of $54.64 and a two-hundred day moving average price of $46.62.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Wednesday, April 8th. Robert W. Baird upped their price target on Xenon Pharmaceuticals from $63.00 to $97.00 and gave the stock an “outperform” rating in a research note on Monday, March 9th. Stifel Nicolaus set a $66.00 price objective on shares of Xenon Pharmaceuticals in a report on Tuesday, February 10th. Guggenheim reissued a “buy” rating and issued a $90.00 target price on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Finally, Jefferies Financial Group set a $100.00 target price on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $73.13.

Insider Transactions at Xenon Pharmaceuticals

In related news, CEO Ian Mortimer sold 7,308 shares of the stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $55.23, for a total value of $403,620.84. Following the sale, the chief executive officer directly owned 19,923 shares of the company’s stock, valued at $1,100,347.29. This represents a 26.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Andrea Difabio sold 1,342 shares of the firm’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $55.23, for a total transaction of $74,118.66. Following the completion of the sale, the insider directly owned 7,301 shares of the company’s stock, valued at approximately $403,234.23. The trade was a 15.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 296,707 shares of company stock worth $17,845,365. 4.07% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Corient Private Wealth LLC purchased a new position in Xenon Pharmaceuticals during the 4th quarter valued at $1,125,000. Mackenzie Financial Corp bought a new stake in shares of Xenon Pharmaceuticals during the fourth quarter worth $210,000. ADAR1 Capital Management LLC boosted its stake in shares of Xenon Pharmaceuticals by 7.9% during the fourth quarter. ADAR1 Capital Management LLC now owns 203,969 shares of the biopharmaceutical company’s stock valued at $9,142,000 after purchasing an additional 14,871 shares during the period. XTX Topco Ltd purchased a new stake in shares of Xenon Pharmaceuticals during the fourth quarter valued at $964,000. Finally, Virtus Investment Advisers LLC grew its holdings in shares of Xenon Pharmaceuticals by 74.0% in the fourth quarter. Virtus Investment Advisers LLC now owns 6,037 shares of the biopharmaceutical company’s stock worth $271,000 after purchasing an additional 2,568 shares during the last quarter. Institutional investors own 95.45% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.